Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
0.9762
USD
-0.93%
-6.13%
+16.42%
This article is reserved for members
Not a member ?
Free registration
Sector Update: Health Care Stocks Higher Late Afternoon
05-09
MT
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise
05-09
MT
X4 Pharmaceuticals, Inc. Draws an Additional Tranche of $20 Million Under Its Existing Loan Facility with Hercules Capital, Inc
05-09
CI
Transcript : X4 Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-07
CI
HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating
04-30
MT
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome
04-29
CI
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome
04-29
MT
Transcript : X4 Pharmaceuticals, Inc. - Special Call
04-29
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules
04-29
DJ
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome
04-29
CI
Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024
03-21
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
03-21
CI
North American Morning Briefing : Investors -2-
03-21
DJ
North American Morning Briefing : Traders Await -2-
12-13
DJ
B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3
12-12
MT
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
12-09
CI
Transcript : X4 Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
11-09
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-09
CI
North American Morning Briefing : Traders Await -2-
11-09
DJ
X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing
11-03
MT
X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing
11-03
MT
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome
23-10-31
CI
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors
23-10-18
CI
Transcript : X4 Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 07:30 AM
23-09-13
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
More about the company
Last Close Price
0.9762
USD
Average target price
4.117
USD
Spread / Average Target
+321.75%
Consensus
1st Jan change
Capi.
+16.42% 164M +7.52% 113B +11.38% 106B -12.64% 22.22B +0.32% 22.27B -3.57% 19.43B -37.85% 17.87B -8.58% 17.24B +37.41% 12.52B -23.95% 8.34B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**